These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 35139297)
1. Effects of an out-of-pocket maximum in Medicare Part D. Parasrampuria S; Anderson GF Am J Manag Care; 2022 Feb; 28(2):e55-e62. PubMed ID: 35139297 [TBL] [Abstract][Full Text] [Related]
2. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon". Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739 [TBL] [Abstract][Full Text] [Related]
3. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations. Odouard IC; Anderson GF; Alexander GC; Ballreich J J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance. DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016 [TBL] [Abstract][Full Text] [Related]
5. Comparing patient OOP spending for specialty drugs in Medicare Part D and employer-sponsored insurance. Parasrampuria S; Sen AP; Anderson GF Am J Manag Care; 2020 Sep; 26(9):388-394. PubMed ID: 32930551 [TBL] [Abstract][Full Text] [Related]
6. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs. Jung K; McBean AM; Kim JA J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470 [TBL] [Abstract][Full Text] [Related]
7. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis. Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722 [TBL] [Abstract][Full Text] [Related]
8. Geographic Variation in the Prevalence of High-Risk Medication Use Among Medicare Part D Beneficiaries by Hospital Referral Region. Chinthammit C; Bhattacharjee S; Axon DR; Slack M; Bentley JP; Warholak TL; Wilson DL; Lo-Ciganic WH J Manag Care Spec Pharm; 2020 Oct; 26(10):1309-1316. PubMed ID: 32996396 [TBL] [Abstract][Full Text] [Related]
9. Cost minimization of medicare part D prescription drug plan expenditures. Patel RA; Lipton HL; Cutler TW; Smith AR; Tsunoda SM; Stebbins MR Am J Manag Care; 2009 Aug; 15(8):545-53. PubMed ID: 19670958 [TBL] [Abstract][Full Text] [Related]
10. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019. Zhou T; Liu P; Dhruva SS; Shah ND; Ramachandran R; Berg KM; Ross JS JAMA Intern Med; 2022 Feb; 182(2):185-195. PubMed ID: 34982097 [TBL] [Abstract][Full Text] [Related]
11. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans. Patel UD; Davis MM J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016 [TBL] [Abstract][Full Text] [Related]
12. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25. Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112 [TBL] [Abstract][Full Text] [Related]
13. Association of low-income subsidy, medicaid dual eligibility, and disability status with high-risk medication use among Medicare Part D beneficiaries. Chinthammit C; Bhattacharjee S; Lo-Ciganic WH; Axon DR; Slack M; Bentley JP; Warholak TL Res Social Adm Pharm; 2022 Apr; 18(4):2634-2642. PubMed ID: 34006485 [TBL] [Abstract][Full Text] [Related]
14. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'. Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981 [TBL] [Abstract][Full Text] [Related]
15. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act. Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519 [TBL] [Abstract][Full Text] [Related]
16. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008. Cheng LI; Rascati KL Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663 [TBL] [Abstract][Full Text] [Related]
17. Out-of-Pocket Costs for Long-Acting Injectable and Oral Antipsychotics Among Medicare Patients With Schizophrenia. Doshi JA; Li P; Geng Z; Seo S; Patel C; Benson C Psychiatr Serv; 2024 Apr; 75(4):333-341. PubMed ID: 37960866 [TBL] [Abstract][Full Text] [Related]
18. Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry. Padula WV; Ballreich J; Anderson GF Appl Health Econ Health Policy; 2018 Dec; 16(6):753-763. PubMed ID: 30058011 [TBL] [Abstract][Full Text] [Related]
19. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D. Blumberg DM; Prager AJ; Liebmann JM JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853 [TBL] [Abstract][Full Text] [Related]
20. Access to oral osteoporosis drugs among female Medicare Part D beneficiaries. Lin CW; Karaca-Mandic P; McCullough JS; Weaver L Womens Health Issues; 2014; 24(4):e435-45. PubMed ID: 24837398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]